| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Helander, A
(författare)
-
Biological markers in alcoholism
- 2003
-
Ingår i: Journal of neural transmission. Supplementum. - Vienna : Springer Vienna. - 0303-6995. ; :66, s. 15-32
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Magyar, K., et al.
(författare)
-
Deprenyl: from chemical synthesis to neuroprotection.
- 2006
-
Ingår i: Journal of neural transmission. Supplementum. - 0303-6995. ; 71, s. 143-156
-
Tidskriftsartikel (refereegranskat)abstract
- During the last decades (-)-deprenyl has become the golden standard of MAO-B inhibitors. It possesses dopamine potentiating and antioxidant properties; however, its effects cannot be explained solely by the enzyme inhibitory action. (-)-Deprenyl prevents the toxicity of certain selective neurotoxins and recently it was demonstrated to increase cell-cell adhesion as well. The complexity of its pharmacological effects reflects the action of both the parent compound and the active metabolites. (-)-Deprenyl and related propargylamines (DRPs) show neuroprotective features in a variety of in vitro and in vivo models that is dependent on the propargyl moiety. The main presumptive targets to date include glyceraldehyde-3-phosphate dehydrogenase, poly(ADP-ribose) polymerase, some kinase cascades, as well as pro- and antiapoptotic proteins, beside the inhibition of MAO-B. The antiapoptotic activity of DRPs converges upon the maintenance of mitochondrial integrity, due to the initiation of a comp
|
|
| 10. |
- Rajda, Cecilia, et al.
(författare)
-
Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis
- 2007
-
Ingår i: Journal of neural transmission. Supplementum. - 0303-6995. ; :72, s. 323-329
-
Tidskriftsartikel (refereegranskat)abstract
- Multiple sclerosis (MS) is a chronic, demyelinating disease of unknown origin. Sophisticated analytical methods have made it possible to measure small biologically active molecules at low endogenous levels, and understand their role in the network of other biologically active compounds actively involved in inflammatory and neurodegenerative processes. Evidence is accumulating as concerns the disturbances of the kynurenine pathway and redox changes in MS. A new promising metabolite of the kynurenine pathway seems to beneficially influence experimental allergic encephalomyelitis. More clinical evidence is needed to prove the role of kynurenic acid analogues and/or enzyme inhibitors as potential medications in MS in the future. Various compounds have been shown to be important in the pathophysiological processes of the disease and are targets for pharmaceutical intervention.
|
|
